Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…
recession Dr. Heitor Costa, Executive Director at Apifarm, Portugal, discusses the country’s economic situation and the presence of international pharmaceutical companies despite the recession. He further discusses the current policy and influence of generics on the pharmaceutical industry, and why he feels investment in Portugal is so crucial at a time…
generics “The IMS Health figures show around three to four percent growth in the marketplace,” remarks Raymund Azurin, chief executive of Zuellig Pharma Philippines, “but we are now at a point in time where the business models in this market are changing. The rise of generics and increasing government intervention…
Generics Kenneth Y Hartigan-Go, Acting Director General of the Food and Drug Administration Philippines (FDA) discusses the current state of regulations processes, strategies that the FDA are applying to the major challenges being presented, and further elaborates on the affect that the universal healthcare would have on the Filipino market. One…
Generics Armando Esguerra, President of Chira Pharmaceuticals, Philippines, explains the concept of chirality, why it is relevant and extremely important in the pharmaceutical industry, and what have been the major challenges and successes of the company since its founding. CHIRA Pharmaceuticals as a company was founded on the concept of…
Generics Fransisco Velez, Founder and Director General of toLife, discusses the challenges facing generics companies in Portugal today, and his ambitions to further grow his company over the years to come. What was the inspiration for creating toLife? I worked at Janssen Cilag for more than 20 years in…
Generics João Madeira, General Manager of Mylan Portugal provides an overview of the state of generics in Portugal today, discussing structural issues related to Portugal’s low generic medicines penetration, ways to better promote healthcare savings, and Mylan’s own contributions to ensuring a sustainable marketplace in Portugal. Prior to Mylan, you worked…
Generics Hernâni Sério, General Manager of the Portuguese affiliate, Fresenius Kabi, discusses the challenges of the hospital market, as well as his company’s strategic positioning in a market with few competitors in the manufacturing and export business. How has Fresenius Kabi developed since the acquisition of Labesfal in 2005? This…
Generics As a company focused entirely on innovation, Janssen has remained dedicated to bringing groundbreaking new products to Portugal, ensuring access in Portugal is as stellar as anywhere else. Gisella Dante, General Manager of Janssen Portugal, outlines the affiliate’s strategy to keep investments in Portugal including local partnerships. Would you…
Generics Paulo Lilaia, CEO of Generis Portugal give an insight into the role of generics in the Portuguese marketplace as well as his company’s strategy to expand in both the local and international markets. You are both the President of Apogen and CEO of Generis. How do you balance your…
See our Cookie Privacy Policy Here
